Company Overview and News

0
Bri-Chem Announces Results of 2018 Annual General Meeting

2018-06-15 globenewswire
EDMONTON, Alberta, June 15, 2018 (GLOBE NEWSWIRE) -- Bri-Chem Corp. (“Bri-Chem” or “Company”) (TSX:BRY), a leading North American oilfield chemical distribution and blending company, is pleased to announce that all the nominees listed in the Management Information Circular dated May 10, 2018 were elected as directors of the Company at its annual general meeting held on June 14, 2018.
BRY

0
Bri-Chem Announces 2018 First Quarter Financial Results

2018-05-14 globenewswire
EDMONTON, Canada, May 14, 2018 (GLOBE NEWSWIRE) -- Bri-Chem Corp. (“Bri-Chem” or “Company”) (TSX:BRY), a leading North American wholesale distributor and manufacturer of oil and gas drilling fluids reports the following 2018 first quarter financial results.
BRY

0
Bri-Chem Announces 2018 First Quarter Financial Results Conference Call

2018-05-11 globenewswire
EDMONTON, Alberta, May 11, 2018 (GLOBE NEWSWIRE) -- Bri-Chem Corp. (“Bri-Chem” or “Company”) (TSX:BRY), a leading North American wholesale distributor and manufacturer of oil and gas drilling fluids will hold its 2018 first quarter financial results conference call to discuss Bri-Chem’s results, outlook and related matters at 1:00 pm (EDT), Tuesday, May 15, 2018. Details for the conference call are as follows:
BRY

0
Bri-Chem Announces 2017 Fourth Quarter and Year End Financial Results

2018-03-29 globenewswire
EDMONTON, Alberta, March 29, 2018 (GLOBE NEWSWIRE) -- Bri-Chem Corp. (“Bri-Chem” or “Company”) (TSX:BRY), a leading North American wholesale distributor and manufacturer of oil and gas drilling fluids is pleased to announce its 2017 fourth quarter and year-end financial results.
BRY

0
Bri-Chem Announces 2017 Fourth Quarter and Year End Results Conference Call

2018-03-26 globenewswire
EDMONTON, Alberta, March 26, 2018 (GLOBE NEWSWIRE) -- Bri-Chem Corp. (“Bri-Chem” or “Company”) (TSX:BRY), a leading North American wholesale distributor and manufacturer of oil and gas drilling fluids will hold its 2017 fourth quarter and year end conference call to discuss Bri-Chem’s results, outlook and related matters at 1:00 pm (EDT), Thursday, March 29, 2018. Details for the conference call are as follows:
BRY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to TSX:BRY / Bri Chem Corp on message board site Silicon Investor.

BOILER ROOM OPERATOR BRYANT CRAGUN MAKES COMEBACK. Gary Dobry Subpoenas 41 SI Aliases
Kobe Bryant Sex Charges Brio Technology, Inc. (BRYO)
MOrgan Fund - More CRAP from Bryant Cragun u0026 His CrimCrew Northland Cranberries Inc (CBRYA)
Embryo Development - EMBR